Please Wait
Applying Filters...
Menu
Xls
2D Structure
Also known as: 14698-29-4, Nidantin, Dioxacin, Emyrenil, Utibid, Prodoxal
Molecular Formula
C13H11NO5
Molecular Weight
261.23  g/mol
InChI Key
KYGZCKSPAKDVKC-UHFFFAOYSA-N
FDA UNII
L0A22B22FT

Synthetic antimicrobial related to NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-ethyl-8-oxo-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid
2.1.2 InChI
InChI=1S/C13H11NO5/c1-2-14-5-8(13(16)17)12(15)7-3-10-11(4-9(7)14)19-6-18-10/h3-5H,2,6H2,1H3,(H,16,17)
2.1.3 InChI Key
KYGZCKSPAKDVKC-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCN1C=C(C(=O)C2=CC3=C(C=C21)OCO3)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
L0A22B22FT
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Acid, Oxolinic

2. Gramurin

3. Oxolinate, Sodium

4. Sodium Oxolinate

2.3.2 Depositor-Supplied Synonyms

1. 14698-29-4

2. Nidantin

3. Dioxacin

4. Emyrenil

5. Utibid

6. Prodoxal

7. Prodoxol

8. Gramurin

9. Oksaren

10. Oxolinic

11. Ossian

12. Uroxol

13. Acide Oxolinique

14. Uritrate

15. Urotrate

16. Oxoboi

17. Pietil

18. Starner

19. Ultibid

20. Acido Oxolinico

21. Uro-alvar

22. Acidum Oxolinicum

23. Nsc-110364

24. Urinox

25. 5-ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic Acid

26. W 4565

27. 5-ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic Acid

28. 5-ethyl-8-oxo-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic Acid

29. Aqualinic

30. Nsc 110364

31. 1-ethyl-6,7-methylenedioxy-4-quinolone-3-carboxylic Acid

32. Mfcd00056775

33. 5-ethyl-5,8-dihydro-8-oxo-1,3-dioxolo(4,5-g)quinoline-7-carboxylic Acid

34. 1-ethyl-1,4-dihydro-6,7-methylenedioxy-4-oxo-3-quinolinecarboxylic Acid

35. Oxolinic Acid Impurity B

36. 1,3-dioxolo(4,5-g)quinoline-7-carboxylic Acid, 5-ethyl-5,8-dihydro-8-oxo-

37. L0a22b22ft

38. Chebi:138856

39. 1,3-dioxolo[4,5-g]quinoline-7-carboxylic Acid, 5-ethyl-5,8-dihydro-8-oxo-

40. Nsc110364

41. Ncgc00015762-06

42. Cistopax

43. Orthurine

44. Tiurasin

45. Acido Ossolico

46. Cas-14698-29-4

47. Dsstox_cid_1089

48. W-4565

49. Dsstox_rid_75935

50. Dsstox_gsid_21089

51. 16172-03-5

52. Acido Ossolico [dcit]

53. 5-ethyl-5,8-dihydro-8-oxo-1,3-dioxolo[4,5-g]quinoline-7-carboxylic Acid

54. Acide Oxolinique [inn-french]

55. Acido Oxolinico [inn-spanish]

56. Acidum Oxolinicum [inn-latin]

57. Ccris 6301

58. Hsdb 3243

59. Sr-01000076042

60. Einecs 238-750-8

61. Brn 0620635

62. Unii-l0a22b22ft

63. Inoxyl

64. Oxolinic-acid

65. Oxolinic Acid [usan:inn:ban]

66. S-0208

67. Aqualinic (tn)

68. Quinolone Antibiotic

69. Prestwick_629

70. Spectrum_001397

71. Prestwick0_000193

72. Prestwick1_000193

73. Prestwick2_000193

74. Prestwick3_000193

75. Spectrum2_000933

76. Spectrum3_001490

77. Spectrum4_000073

78. Spectrum5_001176

79. Lopac-o-0877

80. 5,8-dihydro-5-ethyl-8-oxo-1,3-dioxolo[4,5-g]quinoline-7-carboxylic Acid

81. Oxolinic Acid [mi]

82. Oxolinic Acid (usan/inn)

83. Oxolinic Acid [inn]

84. Lopac0_000952

85. Oprea1_169598

86. Schembl24445

87. Bspbio_000145

88. Bspbio_003079

89. Kbiogr_000625

90. Kbioss_001877

91. Oxolinic Acid [hsdb]

92. Oxolinic Acid [usan]

93. Mls000028501

94. Divk1c_000659

95. Spectrum1502030

96. Spbio_000866

97. Spbio_002066

98. Oxolinic Acid [mart.]

99. Bpbio1_000161

100. Chembl416755

101. Zinc1875

102. Oxolinic Acid [who-dd]

103. Dtxsid1021089

104. Hms502a21

105. Kbio1_000659

106. Kbio2_001877

107. Kbio2_004445

108. Kbio2_007013

109. Kbio3_002579

110. Ninds_000659

111. Hms1568h07

112. Hms1921f12

113. Hms2092p09

114. Hms2095h07

115. Hms3262p06

116. Hms3712h07

117. Oxolinic Acid, Analytical Standard

118. Pharmakon1600-01502030

119. Oxolinic Acid, Quinolone Antibiotic

120. Act03284

121. Hy-b1002

122. Tox21_110216

123. Tox21_202787

124. Tox21_500952

125. Ac8065

126. Bbl009934

127. Ccg-39666

128. Nsc758177

129. Oxolinic Acid [ep Monograph]

130. S4537

131. Stk801351

132. 5-ethyl-8-oxo-5-hydro-2h-1,3-dioxoleno[4,5-g]quinoline-7-carboxylic Acid

133. Akos000282622

134. Tox21_110216_1

135. Cs-4499

136. Db13627

137. Lp00952

138. Nsc-758177

139. Sdccgsbi-0050926.p004

140. Idi1_000659

141. Ncgc00015762-01

142. Ncgc00015762-02

143. Ncgc00015762-03

144. Ncgc00015762-04

145. Ncgc00015762-05

146. Ncgc00015762-07

147. Ncgc00015762-08

148. Ncgc00015762-09

149. Ncgc00015762-10

150. Ncgc00015762-11

151. Ncgc00015762-13

152. Ncgc00015762-17

153. Ncgc00093361-02

154. Ncgc00093361-03

155. Ncgc00093361-04

156. Ncgc00093361-05

157. Ncgc00260333-01

158. Ncgc00261637-01

159. As-12087

160. Smr000058314

161. Sy066716

162. Sbi-0050926.p003

163. Db-042865

164. Eu-0100952

165. Ft-0637128

166. Oxolinic Acid 100 Microg/ml In Acetonitrile

167. Vu0243182-3

168. D02301

169. O 0877

170. Wln: T C566 Do Fo Jn Mv Ehj J2 Lvq

171. 698o294

172. A808577

173. Q287840

174. Sr-01000076042-1

175. Sr-01000076042-4

176. Sr-01000076042-6

177. W-108119

178. Brd-k73394555-001-08-6

179. 5-ethyl-5,3-dioxolo[4,5-g]quinoline-7-carboxylic Acid

180. F3351-0487

181. 1-ethyl-1,7-methylenedioxy-4-oxo-3-quinolinecarboxylic Acid

182. Oxolinic Acid, European Pharmacopoeia (ep) Reference Standard

183. 1,5-g]quinoline-7-carboxylic Acid, 5-ethyl-5,8-dihydro-8-oxo-

184. 1.4-dihydro-1-ethyl-6,7-methylenedioxy-4-oxoquinoline-3-carboxylic Acid

185. 5-ethy1-5,8-dihydro-8-oxo-1,3-dioxolo[4,5]quinoline-7-carboxylic Acid

186. 5-ethyl-5,8-dihydro-8-oxo(1,3)dioxolo(4,5-g)quinoline-7-carboxylic Acid

187. 5-ethyl-8-oxo-2h,5h,8h-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic Acid

188. 5-ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic Acid #

189. W-4565; 5,8-dihydro-5-ethyl-8-oxo-1,3-dioxolo[4,5-g]quinoline-7-carboxylic Acid

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 261.23 g/mol
Molecular Formula C13H11NO5
XLogP3-0.2
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count6
Rotatable Bond Count2
Exact Mass261.06372245 g/mol
Monoisotopic Mass261.06372245 g/mol
Topological Polar Surface Area76.1 Ų
Heavy Atom Count19
Formal Charge0
Complexity446
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Therapeutic Uses

Anti-Infective Agents, Quinolone; Anti-Infective Agents, Urinary

National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)


DRUG HAS CHEMICAL STRUCTURE, MECHANISM OF ACTION, SPECTRUM OF ACTIVITY & POTENTIAL FOR TOXICITY THAT RESEMBLES NALIDIXIC ACID.

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 182


OXOLINIC ACID IS ALTERNATIVE FORM OF THERAPY FOR PENICILLIN-SENSITIVE OR CEPHALOSPORIN-SENSITIVE ADULT WHO HAS RECURRENT URINARY TRACT INFECTION CAUSED BY SUSCEPTIBLE ESCHERICHIA COLI OR PROTEUS MIRABILIS THAT IS NOT COMPLICATED BY BACTEREMIA.

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 183


...EXERTS IN VITRO ACTIVITY AGAINST MOST GRAM-NEGATIVE AEROBIC BACILLI THAT CAUSE BACTERIAL URINARY TRACT INFECTIONS. MAJORITY OF ESCHERICHIA COLI, KLEBSIELLA SP, ENTEROBACTER SP & PROTEUS SP ARE SUSCEPTIBLE. ... SALMONELLA, SHIGELLA & NEISSERIA (MENINGITIDIS, GONORRHEAE) ARE SUSCEPTIBLE...STAPHYLOCOCCUS AUREUS...

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 182


For more Therapeutic Uses (Complete) data for OXOLINIC ACID (6 total), please visit the HSDB record page.


4.2 Drug Warning

PSEUDOMONAS AERUGINOSA & ACINETOBACTER CALCOACETICUS (VAR LIVOFFI & VAR ANITRATUS) ARE UNIFORMLY RESISTANT...

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 182


WHEN BACTERIAL RESISTANCE DEVELOPS...IT IS USUALLY RAPID. THEREFORE, IF FOLLOW-UP CULTURES INDICATE THAT URINE IS NOT STERILE WITHIN 48-72 HR, TREATMENT CAN PROBABLY BE CONSIDERED FAILURE SINCE ORGANISM BY THEN WILL HAVE DEVELOPED RESISTANCE. ... CROSS RESISTANCE TO NALIDIXIC ACID HAS BEEN REPORTED.

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 794


...HAS STIMULATORY EFFECT ON CNS, & SHOULD NOT BE PRESCRIBED FOR PT WITH KNOWN SEIZURE DISORDERS.

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 184


...HAS FAIRLY NARROW ANTIBACTERIAL SPECTRUM &, THEREFORE, BACTERIAL CULTURE & SENSITIVITY TESTS GENERALLY SHOULD BE PERFORMED PRIOR TO ITS USE.

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 794


For more Drug Warnings (Complete) data for OXOLINIC ACID (7 total), please visit the HSDB record page.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Topoisomerase II Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)


Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)


Anti-Infective Agents, Urinary

Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)


5.2 ATC Code

J - Antiinfectives for systemic use

J01 - Antibacterials for systemic use

J01M - Quinolone antibacterials

J01MB - Other quinolones

J01MB05 - Oxolinic acid


5.3 Absorption, Distribution and Excretion

AFTER INGESTION OF OXOLINIC ACID, 5-ETHYL-5,8-DIHYDRO-8 -OXO-1,3-DIOXOLO-[4,5-G]QUINOLINE-7-CARBOXYLIC ACID, BY HUMAN SUBJECTS, URINE CONTAINED SMALL QUANTITY OF BIOLOGICALLY-INACTIVE & UNIDENTIFIED OXOLINIC ACID COMPLEX, BUT NO UNCHANGED OXOLINIC ACID.

The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 1: A Review of the Literature Published Between 1960 and 1969. London: The Chemical Society, 1970., p. 206


OF ORAL DOSE OF ANTIBACTERIAL, (14)C-OXOLINIC ACID, THERE WAS EXCRETED IN 24-HR URINE & FECES RESPECTIVELY, 27 & 41% BY RAT, 19 & 14% BY DOG, 49 & 37% BY RABBIT, & 35 & 10% BY MAN. BLOOD LEVELS OF (14)C PEAKED AFTER 4 HR IN DOG & MAN, & AFTER 6 HR IN RAT & RABBIT.

The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 2: A Review of the Literature Published Between 1970 and 1971. London: The Chemical Society, 1972., p. 111


AFTER ORAL ADMIN...RAPIDLY ABSORBED FROM GI TRACT. PEAK SERUM CONCN OF BIOLOGICALLY ACTIVE UNCONJUGATED DRUG ARE ATTAINED IN 2-4 HR & RANGE FROM 1.8-3.6 UG/ML. LOWER SERUM LEVELS...OCCUR DURING 1ST 3 DAYS OF DOSING, SUGGESTING SLOW DISTRIBUTION... PROTEIN BINDING OF DRUG IS ABOUT 77-81%.

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 183


750 MG ADMIN TWICE/DAY FOR 7 DAYS STUDIED IN 10 HEALTHY WOMEN. WHEN TAKEN WITH FOOD, EXCRETION RETARDED BY 6 HR BUT 48 HR RECOVERY NOT DECR.

MANNISTO PT; CLIN PHARMACOL THER 19(JAN) 37-46 (1976)


For more Absorption, Distribution and Excretion (Complete) data for OXOLINIC ACID (6 total), please visit the HSDB record page.


5.4 Metabolism/Metabolites

YIELDS 1-ETHYL-1,4-DIHYDRO-7-HYDROXY-6-METHOXY-6-OXOQUINOLINE-3-CARBOXYLIC ACID IN RAT, RABBIT, DOG; YIELDS OXOLINOYL-BETA-D-GLUCURONIC ACID IN RAT, RABBIT, DOG; CREW, MC, MELGAR, MD, HAYNES, LJ, GALA, RL, & DICARLO, FJ, XENOBIOTICA, 1, 193 (1971). /FROM TABLE/

Goodwin, B.L. Handbook of Intermediary Metabolism of Aromatic Compounds. New York: Wiley, 1976., p. 11


MAJOR URINARY METABOLITE WAS GLUCURONIDE OF OXOLINIC ACID...THIS COMPD WAS BIOLOGICALLY ACTIVE WHEREAS ALMOST ALL DRUG GLUCURONIDES ARE BIOLOGICALLY INERT...

The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 1: A Review of the Literature Published Between 1960 and 1969. London: The Chemical Society, 1970., p. 206


5.5 Biological Half-Life

AFTER REPEATED DOSING, BIPHASIC EXCRETION PATTERN HAS BEEN OBSERVED. INITIAL PHASE IS RAPID WITH T/2 OF ABOUT 1.5 HR, & IS FOLLOWED BY SLOW PHASE WITH T/2 OF ABOUT 15 HR. URINARY CONCN OF UNCONJUGATED DRUG RANGE FROM 15-155 UG/ML IN PT WITH NORMAL RENAL FUNCTION.

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 183


5.6 Mechanism of Action

...INTERFERENCE WITH DEOXYRIBONUCLEIC ACID (DNA) SYNTH. OXOLINIC ACID, HOWEVER, HAS DEMONSTRATED 10-FOLD GREATER /THAN NALIDIXIC ACID/ ABILITY TO INHIBIT DNA REPLICATION, WHICH IS PARALLELED BY ITS GREATER IN VITRO ACTIVITY FOR ENTEROBACTERIACEAE.

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 182